Literature DB >> 1381393

Complex of soluble human IL-6-receptor/IL-6 up-regulates expression of acute-phase proteins.

A Mackiewicz1, H Schooltink, P C Heinrich, S Rose-John.   

Abstract

IL-6 is a major regulator of acute phase protein synthesis in the liver. It exerts its action via a plasma membrane receptor consisting of two subunits, a ligand binding 80-kDa glycoprotein and a 130-kDa glycoprotein involved in signal transduction. We genetically generated a soluble form of the 80-kDa subunit of the human IL-6R (shIL-6R) in mouse fibroblasts (NIH/3T3 cells). The shIL-6R added to human hepatoma cells (HepG2) amplified the induction of alpha 1-antichymotrypsin and haptoglobin by IL-6 at the mRNA and protein level. Moreover, a model for a liver permanently exposed to high IL-6 concentrations has been developed; HepG2 cells were stably transfected with human IL-6-cDNA; 10(6) of the transfected cells (HepG2-IL-6) synthesized and secreted 2 micrograms of IL-6 within 24 h. Incubation of these cells with endogenous or exogenous IL-6 did not result in acute-phase protein induction. However, these IL-6-desensitized cells responded to other cytokines such as leukemia inhibitory factor, transforming growth factor beta 1, and IFN-gamma, known to modulate acute phase protein synthesis in the liver. Incubation of HepG2-IL-6 cells with shIL-6R reconstituted their responsiveness to IL-6 in a dose- and time-dependent manner. The possible biologic role that might be played by the shIL-6R in disease is discussed.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1381393

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  82 in total

1.  A single amino acid substitution (Trp(666)-->Ala) in the interbox1/2 region of the interleukin-6 signal transducer gp130 abrogates binding of JAK1, and dominantly impairs signal transduction.

Authors:  C Haan; H M Hermanns; P C Heinrich; I Behrmann
Journal:  Biochem J       Date:  2000-07-01       Impact factor: 3.857

2.  Estrogen suppresses heptatic IκB expression during short-term alcohol exposure.

Authors:  Eric G Lee; Bethany M Mickle-Kawar; Lester A Reinke; Randle M Gallucci
Journal:  Inflamm Res       Date:  2012-06-06       Impact factor: 4.575

3.  Engineering human interleukin-6 to obtain variants with strongly enhanced bioactivity.

Authors:  C Toniatti; A Cabibbo; E Sporena; A L Salvati; M Cerretani; S Serafini; A Lahm; R Cortese; G Ciliberto
Journal:  EMBO J       Date:  1996-06-03       Impact factor: 11.598

Review 4.  Lack of knowledge: breast cancer and the soluble interleukin-6 receptor.

Authors:  Heike Knüpfer; Rainer Preiss
Journal:  Breast Care (Basel)       Date:  2010-06       Impact factor: 2.860

5.  Low follicular fluid IL-6 levels in IVF patients are associated with increased likelihood of clinical pregnancy.

Authors:  Tugba Altun; Sangita Jindal; Keri Greenseid; Jun Shu; Lubna Pal
Journal:  J Assist Reprod Genet       Date:  2010-11-03       Impact factor: 3.412

Review 6.  Adjunct corticosteroid treatment in patients with pneumonia: A precision medicine approach.

Authors:  Srdjan Gavrilovic; Ana Andrijevic; Aida Mujakovic; Yewande Odeyemi; Belma Paralija; Ognjen Gajic
Journal:  Bosn J Basic Med Sci       Date:  2019-11-08       Impact factor: 3.363

7.  Trans-signaling is a dominant mechanism for the pathogenic actions of interleukin-6 in the brain.

Authors:  Iain L Campbell; Maria Erta; Sue Ling Lim; Ricardo Frausto; Ulrike May; Stefan Rose-John; Jürgen Scheller; Juan Hidalgo
Journal:  J Neurosci       Date:  2014-02-12       Impact factor: 6.167

Review 8.  Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway.

Authors:  P C Heinrich; I Behrmann; G Müller-Newen; F Schaper; L Graeve
Journal:  Biochem J       Date:  1998-09-01       Impact factor: 3.857

9.  Cellular senescence or EGFR signaling induces Interleukin 6 (IL-6) receptor expression controlled by mammalian target of rapamycin (mTOR).

Authors:  Christoph Garbers; Fabian Kuck; Samadhi Aparicio-Siegmund; Kirstin Konzak; Mareike Kessenbrock; Annika Sommerfeld; Dieter Häussinger; Philipp A Lang; Dirk Brenner; Tak W Mak; Stefan Rose-John; Frank Essmann; Klaus Schulze-Osthoff; Roland P Piekorz; Jürgen Scheller
Journal:  Cell Cycle       Date:  2013-09-18       Impact factor: 4.534

Review 10.  The varying faces of IL-6: From cardiac protection to cardiac failure.

Authors:  Jillian A Fontes; Noel R Rose; Daniela Čiháková
Journal:  Cytokine       Date:  2015-01-31       Impact factor: 3.861

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.